Vaccines, Volume 10, Issue 2
February 2022 - 207 articles
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story: Shigella sonnei and flexneri remain among the top bacterial causes of dysentery and severe diarrhea in children. Several vaccine developers are in advanced clinical studies with highly promising multivalent formulations; a safe and efficacious Shigella vaccine would represent a great scientific achievement. Nonetheless, such a vaccine would arrive in the context of increasingly crowded and costly childhood immunization programs, among a myriad of other new and improved vaccines currently or soon on the market. There is thus no guarantee that a Shigella vaccine would become an adoption priority by those low- and middle-income countries that could benefit the most. We discuss some of the major determinants of the introduction of Shigella vaccines and the importance of developing a succinct, compelling public health value proposition. View this paper